The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.

Over a three year period we have studied the effect of either a one year course of Carbimazole or a single dose of radioiodine in a group of 46 patients with Graves' disease. Initially, in untreated patients LATS-P was present in 39 (85%) but at the end of the study was only detectable in 19 (41%). The clinical outcome in 29 patients initially treated with carbimazole correlated well with changes in serum LATS-P which persisted in 18. Thirteen of these ultimately required radioiodine or sub-total thyroidectomy. With radioiodine two patterns of response were seen, in some LATS-P levels declined, whereas in others transient increases were seen usually during the first year but subsequently fell. There was no difference in clinical response between the two groups. Overall, the study indicates that serum LATS-P is related to the clinical course of Graves' disease but there remains a minority of patients in whom the activity cannot be detected.
AuthorsC A Hardisty, A Fowles, D S Munro
JournalClinical endocrinology (Clin Endocrinol (Oxf)) Vol. 20 Issue 5 Pg. 597-605 (May 1984) ISSN: 0300-0664 [Print] ENGLAND
PMID6547647 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoglobulin G
  • Iodine Radioisotopes
  • Carbimazole
  • Long-Acting Thyroid Stimulator
  • Adult
  • Aged
  • Carbimazole (therapeutic use)
  • Female
  • Graves Disease (drug therapy, immunology, radiotherapy)
  • Humans
  • Immunoglobulin G (analysis)
  • Iodine Radioisotopes (therapeutic use)
  • Long-Acting Thyroid Stimulator (analysis)
  • Male
  • Middle Aged
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: